GlassScriptPhysician profile
James Alan Henderson
NPI 1689840514
$6,933.29
in general payments reported to CMS, 2019-2025
47 companies · $916 in 2025
The $916 reported for 2025 was more than what 84% of Adolescent Medicine (Family Medicine) providers received nationally (typical 2025 total: $135).
See the full distribution for Adolescent Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $1,082 · 2021: $1,112 · 2022: $696 · 2023: $1,128 · 2024: $1,165 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,058.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $889.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $613.20 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $403.46 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Dexcom, INC. | $271.72 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $255.97 | 2019-2023 | |
| Abbott Laboratories | $244.98 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $239.10 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.00 | 2020-2024 | Jardiance |
| Abbvie INC. | $213.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $199.91 | 2019-2023 | |
| Amarin Pharma, INC. | $195.81 | 2019-2021 | |
| Kerecis Limited | $194.83 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Convatec INC. | $184.60 | 2024 | |
| Janssen Pharmaceuticals, INC | $160.06 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.